Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People
University Of Nigeria Teaching Hospital
220 participants
Jul 23, 2025
INTERVENTIONAL
Conditions
Summary
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Eligibility
Inclusion Criteria4
- Obesity (defined as body mass index ≥ 30kg/m2),
- Fasting plasma glucose (<7.0mmol/L)
- No medical treatment for weight control in the previous 12 months
- No participation in a current clinical trial
Exclusion Criteria4
- Obesity (defined as body mass index ≥ 30kg/m2),
- Fasting plasma glucose (<7.0mmol/L)
- No medical treatment for weight control in the previous 12 months
- No participation in a current clinical trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily
Starch-based, identical looking placebo
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07297290